Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 18/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 16/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604143 | 0.85 | HTR2B (0.69) | MEN1KMT2AHTR2BHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1920934 | 0.84 | HTR2B (0.68) | MEN1KMT2AHTR2BHTTSMN1; SMN2 | |
| SCHEMBL1604201 | 0.80 | HTT (0.75) | MEN1KMT2AHTR2BHTTSMN1; SMN2 | |
| SCHEMBL5043027 | 0.77 | MEN1 (0.60) | MEN1KMT2A | |
| SCHEMBL19444681 | 0.77 | KDM4E (0.62) | MEN1KMT2A | |
| SCHEMBL12533525 | 0.76 | MEN1 (0.66) | MEN1KMT2AHTR2BHTTSMN1; SMN2 | |
| SCHEMBL1604148 | 0.76 | HTR2B (0.70) | MEN1KMT2AHTR2BHTTSMN1; SMN2 | |
| SCHEMBL10326441 | 0.75 | IRAK4 (0.52) | MEN1KMT2A | |
| SCHEMBL10343587 | 0.75 | IRAK4 (0.52) | MEN1KMT2A | |
| SCHEMBL13060020 | 0.73 | MEN1 (0.78) | MEN1KMT2AHTR2BHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797099-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | Epix Delaware, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006034511-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | claimed |
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20100280050-A1 | Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis | PGXHEALTH, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280050-A1 | Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis | PGXHEALTH, LLC | 2010-11-04 | — | — | US | disclosed |
| EP-1797099-B1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE INC (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-1622914-A4 | NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS | EPIX DELAWARE INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1797099-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | Epix Delaware, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2006034511-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1622914-A2 | NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004089312-A2 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280050-A1 | Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis | HTR2B, HTR3B, HTR1B | MEN1 4310/4885KMT2A 2743/4885HTR2B 1/4885 |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR5A, HTR3A, HTR1A | MEN1 2389/4885KMT2A 4258/4885HTR2B 11/4885 |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | MEN1 2833/4885KMT2A 3770/4885HTR2B 5/4885 |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR2B, HTR3B, HTR1B | MEN1 4118/4885KMT2A 3047/4885HTR2B 1/4885 |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | HTR5A, HTR3A, HTR1A | MEN1 2784/4885KMT2A 4320/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.